Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 14/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.62 |
| ▸ | ACLY | P53396 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307810 | 0.92 | ALOX15 (0.73) | HCAR2ALOX15MAPK1GRIK1KDM4E | |
| SCHEMBL22022932 | 0.91 | HCAR2 (0.71) | HCAR2ALOX15MAPK1GRIK1KDM4E | |
| SCHEMBL22022862 | 0.91 | HCAR2 (0.65) | HCAR2ALOX15MAPK1GRIK1ACLY | |
| SCHEMBL27520024 | 0.91 | KDM4E (0.67) | HCAR2ALOX15MAPK1GRIK1KDM4E | |
| SCHEMBL22022930 | 0.90 | KDM4E (0.64) | HCAR2ALOX15MAPK1GRIK1KDM4E | |
| SCHEMBL22022898 | 0.90 | HCAR2 (0.70) | HCAR2ALOX15MAPK1GRIK1ACLY | |
| SCHEMBL22022931 | 0.89 | HCAR2 (0.62) | HCAR2ALOX15MAPK1GRIK1ACLY | |
| SCHEMBL22022910 | 0.88 | KDM4E (0.72) | HCAR2ALOX15MAPK1KDM4EALDH1A1 | |
| SCHEMBL22022923 | 0.88 | HCAR2 (0.67) | HCAR2ALOX15MAPK1GRIK1ACLY | |
| SCHEMBL22022902 | 0.87 | HCAR2 (0.60) | HCAR2ALOX15MAPK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054438-A1 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-02-24 | — | — | US | disclosed |
| EP-3662908-A1 | MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054438-A1 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | KCNK2, KCNT2, KCNT1 | HCAR2 165/4885ALOX15 3777/4885MAPK1 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.